Abstract

Enter the text here that is the new abstract information for your application. This section must be no E 0 longer than 30 lines of text. The key to understanding the results of the STEP/Phambili trials is first to model the results of the trial in controlled experiments using mucosal SIV inoculation of rhesus macaques. Thus, we will determine the effectiveness and potential of the Merck trivalent HIV adenovirus 5 vector vaccine (V520) for enhancing susceptibility to S1V in a rhesus macaque model of mucosal HIV transmission. If models of vaccine protection or enhancement are established, the immune mechanisms and inflammation/activation associated with any protective or enhancing effects can be defined in a renewal application. 0'Qvic' am- .,c vii

Public Health Relevance

Understanding the reasons for the failure of the once promising Merck Ad5 HIV vaccine is critical before proceeding with additional HIV vaccine trials. Without a complete understanding of the failed STEP/Phambili trials, the next clinical trial of a HIV vaccine willl be truly empirical human experimentation rather than a rational next step in vaccine development. This we have proposed animal model studies to characterize the virologya nd immunology of the Step/pahmbili trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI082278-02
Application #
7914336
Study Section
Special Emphasis Panel (ZAI1-EC-A (J2))
Program Officer
Miller, Nancy R
Project Start
2009-08-14
Project End
2011-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$1,795,378
Indirect Cost

  Institution

Name
University of California Davis
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618